KYKatherine S. Yang

Katherine S. Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katherine S. Yang has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Colocalization of Cancer-Associated Biomarkers on Single Extracellular Vesicles for Early Detection of Cancer

    by Daniel P. Salem, Laura T. Bortolin, Dan Gusenleitner, Jonian Grosha, Ibukunoluwapo O. Zabroski, Kelly M. Biette, Sanchari Banerjee, Christopher R. Sedlak, Delaney M. Byrne, Bilal F. Hamzeh, et al.


  • Open Access

    Magnetic Silica‐Coated Fluorescent Microspheres (MagSiGlow) for Simultaneous Detection of Tumor‐Associated Proteins

    by Elias A. Halabi, Isabel Gessner, Katherine S. Yang, Jae‐Jun Kim, Rupsa Jana, Hannah M. Peterson, Joshua D. Spitzberg, Ralph Weissleder

    Multiplexed bead assays for solution‐phase biosensing often encounter cross‐over reactions during signal amplification steps, leading to unwanted false positive and high background signals. Current solutions involve complex custom‐designed and costly equipment, limiting their application in simple laboratory setup. In this study, we introduce a straightforward protocol to adapt a multiplexed single‐bead assay to standard fluorescence imaging plates, enabling the simultaneous analysis of thousands of reactions per plate. This approach focuses on the design and synthesis of bright fluorescent and magnetic microspheres (MagSiGlow) with multiple fluorescent wavelengths serving as unique detection markers. The imaging‐based, single‐bead assay, combined with a scripted algorithm, allows the detection, segmentation, and co‐localization on average of 7500 microspheres per field of view across five imaging channels in less than one second. We demonstrate the effectiveness of this method with remarkable sensitivity at low protein detection limits (100 pg/mL). This technique showed over 85 % reduction in signal cross‐over to the solution‐based method after the concurrent detection of tumor‐associated protein biomarkers. This approach holds the promise of substantially enhancing high throughput biosensing for multiple targets, seamlessly integrating with rapid image analysis algorithms.


  • Open Access

    Magnetic Silica‐Coated Fluorescent Microspheres (MagSiGlow) for Simultaneous Detection of Tumor‐Associated Proteins

    by Elias A. Halabi, Isabel Gessner, Katherine S. Yang, Jae‐Jun Kim, Rupsa Jana, Hannah M. Peterson, Joshua D. Spitzberg, Ralph Weissleder

    Multiplexed bead assays for solution‐phase biosensing often encounter cross‐over reactions during signal amplification steps, leading to unwanted false positive and high background signals. Current solutions involve complex custom‐designed and costly equipment, limiting their application in simple laboratory setup. In this study, we introduce a straightforward protocol to adapt a multiplexed single‐bead assay to standard fluorescence imaging plates, enabling the simultaneous analysis of thousands of reactions per plate. This approach focuses on the design and synthesis of bright fluorescent and magnetic microspheres (MagSiGlow) with multiple fluorescent wavelengths serving as unique detection markers. The imaging‐based, single‐bead assay, combined with a scripted algorithm, allows the detection, segmentation, and co‐localization on average of 7500 microspheres per field of view across five imaging channels in less than one second. We demonstrate the effectiveness of this method with remarkable sensitivity at low protein detection limits (100 pg/mL). This technique showed over 85 % reduction in signal cross‐over to the solution‐based method after the concurrent detection of tumor‐associated protein biomarkers. This approach holds the promise of substantially enhancing high throughput biosensing for multiple targets, seamlessly integrating with rapid image analysis algorithms.


  • Top Cited Papers
    Open Access

    Multiplexed analysis of EV reveals specific biomarker composition with diagnostic impact

    by Joshua D. Spitzberg, Scott Ferguson, Katherine S. Yang, Hannah M. Peterson, Jonathan C. T. Carlson, Ralph Weissleder

    Exosomes and extracellular vesicles (EV) are increasingly being explored as circulating biomarkers, but their heterogenous composition will likely mandate the development of multiplexed EV technologies. Iteratively multiplexed analyses of near single EVs have been challenging to implement beyond a few colors during spectral sensing. Here we developed a multiplexed analysis of EV technique (MASEV) to interrogate thousands of individual EVs during 5 cycles of multi-channel fluorescence staining for 15 EV biomarkers. Contrary to the common belief, we show that: several markers proposed to be ubiquitous are less prevalent than believed; multiple biomarkers concur in single vesicles but only in small fractions; affinity purification can lead to loss of rare EV subtypes; and deep profiling allows detailed analysis of EV, potentially improving the diagnostic content. These findings establish the potential of MASEV for uncovering fundamental EV biology and heterogeneity and increasing diagnostic specificity.


  • Single extracellular vesicle analysis for early cancer detection

    by Scott Ferguson, Katherine S. Yang, Ralph Weissleder


  • Open Access

    Single-EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer

    by Scott Ferguson, Katherine S. Yang, Piotr Zelga, Andrew S. Liss, Jonathan C. T. Carlson, Carlos Fernandez del Castillo, Ralph Weissleder

    Tumor cell–derived extracellular vesicles (EVs) are being explored as circulating biomarkers, but it is unclear whether bulk measurements will allow early cancer detection. We hypothesized that a single-EV analysis (sEVA) technique could potentially improve diagnostic accuracy. Using pancreatic cancer (PDAC), we analyzed the composition of putative cancer markers in 11 model lines. In parental PDAC cells positive for KRAS mut and/or P53 mut proteins, only ~40% of EVs were also positive. In a blinded study involving 16 patients with surgically proven stage 1 PDAC, KRAS mut and P53 mut protein was detectable at much lower levels, generally in 3 tumor volume, below clinical imaging capabilities. These findings establish the potential for sEVA for early cancer detection.


  • Open Access

    Single EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer

    by Scott Ferguson, Katherine S. Yang, Piotr Zelga, Andrew S. Liss, Jonathan Carlson, Carlos Fernandez del Castillo, Ralph Weissleder

    Tumor cell derived extracellular vesicles (EV) are being explored as circulating biomarkers for cancer detection. Up to now however, clinical results have been mixed for a number of reasons including the predominant use of bulk measurements, the inability to differentiate tumor from host cell derived vesicles, the general absence of uniquely identifying biomarkers and the unknown frequency of stochastically distributed biomarkers into single circulating vesicles. We hypothesized that a single EV analysis (sEVA) technique could potentially improve diagnostic accuracy necessary to detect early cancers but the actual biomarker frequency and practical detection limits are currently unknown. Using pancreatic cancer, we carefully analyzed the composition of putative cancer markers in 11 established and new patient derived models. In parental PDAC cells positive for KRAS mut and/or P53 mut proteins only ∼40% of EVs were also positive (range: 30-64%). This rate of positivity increased to 57% when additional PDAC biomarkers were considered (MUC1, EGFR, ⍺FG-P4OH) in cell lines. In a blinded study involving 16 patients with surgically proven stage 1 PDAC, KRAS mut and P53 mut protein was detectable at much lower levels, generally in < 0.1% of vesicles. With the analytical capabilities of sEVA however, 15 of the 16 patients with stage 1 PDAC expressed low levels of biomarker positive EV. Using a modeling approach, we estimate that the current PDAC detection limit is at ∼0.1 cm 3 tumor volume, below clinical imaging capabilities. These findings establish the potential for single-EV analysis for early cancer detection.

  • Top Cited Papers
    Open Access

    Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles

    by Franz L. Ricklefs, Quazim Alayo, Harald Krenzlin, Ahmad B. Mahmoud, Maria C. Speranza, Hiroshi Nakashima, Josie L. Hayes, Kyungheon Lee, Leonora Balaj, Carmela Passaro, et al.

    Binding of programmed death ligand-1 (PD-L1) to programmed cell death protein-1 (PD1) leads to cancer immune evasion via inhibition of T cell function. One of the defining characteristics of glioblastoma, a universally fatal brain cancer, is its profound local and systemic immunosuppression. Glioblastoma has also been shown to generate extracellular vesicles (EVs), which may play an important role in tumor progression. We thus hypothesized that glioblastoma EVs may be important mediators of immunosuppression and that PD-L1 could play a role. We show that glioblastoma EVs block T cell activation and proliferation in response to T cell receptor stimulation. PD-L1 was expressed on the surface of some, but not of all, glioblastoma-derived EVs, with the potential to directly bind to PD1. An anti-PD1 receptor blocking antibody significantly reversed the EV-mediated blockade of T cell activation but only when PD-L1 was present on EVs. When glioblastoma PD-L1 was up-regulated by IFN-γ, EVs also showed some PD-L1–dependent inhibition of T cell activation. PD-L1 expression correlated with the mesenchymal transcriptome profile and was anatomically localized in the perinecrotic and pseudopalisading niche of human glioblastoma specimens. PD-L1 DNA was present in circulating EVs from glioblastoma patients where it correlated with tumor volumes of up to 60 cm3. These results suggest that PD-L1 on EVs may be another mechanism for glioblastoma to suppress antitumor immunity and support the potential of EVs as biomarkers in tumor patients.


  • Top Cited Papers

    Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy

    by Katherine S. Yang, Hyungsoon Im, Seonki Hong, Ilaria Pergolini, Andres Fernandez del Castillo, Rui Wang, Susan Clardy, Chen-Han Huang, Craig Pille, Soldano Ferrone, et al.

    Pancreatic ductal adenocarcinoma (PDAC) is usually detected late in the disease process. Clinical workup through imaging and tissue biopsies is often complex and expensive due to a paucity of reliable biomarkers. We used an advanced multiplexed plasmonic assay to analyze circulating tumor-derived extracellular vesicles (tEVs) in more than 100 clinical populations. Using EV-based protein marker profiling, we identified a signature of five markers (PDACEV signature) for PDAC detection. In our prospective cohort, the accuracy for the PDACEV signature was 84% [95% confidence interval (CI), 69 to 93%] but only 63 to 72% for single-marker screening. One of the best markers, GPC1 alone, had a sensitivity of 82% (CI, 60 to 95%) and a specificity of 52% (CI, 30 to 74%), whereas the PDACEV signature showed a sensitivity of 86% (CI, 65 to 97%) and a specificity of 81% (CI, 58 to 95%). The PDACEV signature of tEVs offered higher sensitivity, specificity, and accuracy than the existing serum marker (CA 19-9) or single–tEV marker analyses. This approach should improve the diagnosis of pancreatic cancer.


  • Top Cited Papers

    In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

    by Sean P. Arlauckas, Christopher S. Garris, Rainer H. Kohler, Maya Kitaoka, Michael F. Cuccarese, Katherine S. Yang, Miles A. Miller, Jonathan C. Carlson, Gordon J. Freeman, Robert M. Anthony, et al.

    Tumor-associated macrophages limit anti–PD-1 effects by removing the antibody from CD8 + T cells.